Alnylam, Medtronic to Get Funding for Huntington's Disease Program | GenomeWeb

Alnylam Pharmaceuticals said this week that it has formed a collaboration with Medtronic and the CHDI Foundation to advance an siRNA-based treatment for Huntington's disease.

The drug, ALN-HTT, comprises an siRNA against huntingtin, the gene responsible for the disease, and a Medtronic-developed implantable infusion system designed to deliver the agent to the central nervous system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.